PANTHERx Rare Pharmacy

What if healthcare could be as personalized as your favorite streaming service? In today’s Drug Channels Institute guest post titled “Inside Rare Disease Pharmacy: Lessons in Personalizing Care,” PANTHERx Rare CEO Bansi Nagji explores how 𝗵𝘆𝗽𝗲𝗿-𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹𝗶𝘇𝗮𝘁𝗶𝗼𝗻 is transforming care for people living with rare and orphan diseases, caregivers, and HCPs. From the challenges associated with rare diseases to the innovative model of rare pharmacy, Bansi gives powerful examples of how empathy, data, and precision come together to deliver healthcare at its best. Read the full post: https://lnkd.in/ec6X7Khy #RareDiseaseCare #RarePharmacy #HyperPersonalization #PANTHERxRare Drug Channels Institute, an HMP Global Company

Get the latest jobs and industry news

What does it really take to launch a rare disease therapy successfully? It starts long before FDA approval. In our latest blog, Brittany Effross, PharmD, Director, Implementation at PANTHERx® Rare, reflects on a panel she moderated at the Launch Excellence Summit in Boston and the critical role of early planning, stakeholder collaboration, operational flexibility, and patient access. One message stood out: 𝘀𝘂𝗰𝗰𝗲𝘀𝘀𝗳𝘂𝗹 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗮𝗿𝗼𝘂𝗻𝗱 𝘁𝗵𝗲 𝗿𝗲𝗮𝗹𝗶𝘁𝗶𝗲𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗷𝗼𝘂𝗿𝗻𝗲𝘆. For rare disease therapies, engaging specialty pharmacy early can provide valuable insight into access barriers, operational readiness, and the support patients need to start therapy. 𝗥𝗲𝗮𝗱 𝗕𝗿𝗶𝘁𝘁𝗮𝗻𝘆’𝘀 𝗳𝘂𝗹𝗹 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲: https://lnkd.in/ebYXXy5Y #RareDisease #SpecialtyPharmacy #LaunchExcellence #PatientAccess #PANTHERxRare

Some of the most important drivers of patient outcomes can also be the most difficult to see. In today’s Drug Channels Institute guest post, “Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes,” our VP of Payer Solutions, Jay Weaver, PharmD, MPH, explores why the true value of Rare Pharmacy can be difficult to see through a traditional payer lens. Jay examines the often-unseen clinical and operational work that helps patients access, stay on, and benefit from treatment, and why that work also matters to payers, PBMs, and employer groups. At PANTHERx® Rare, we know from experience that some of the most important contributions a pharmacy makes to patient success happen behind the scenes, long before and long after a prescription is dispensed. Read Jay’s full post: https://lnkd.in/eCuDAHFD #RareDisease #SpecialtyPharmacy #RarePharmacy #PatientOutcomes #PayerStrategy #PANTHERxRare Drug Channels Institute, an HMP Global Company

In rare disease, approval doesn't guarantee patient access. Complex care pathways, fragmented coordination, and therapy disruptions can prevent innovative treatments from reaching their full impact. In our latest article, we explore: - Why commercialization risk continues after launch - How fragmentation affects patients and therapy adoption - What organizations can do to build a more coordinated patient journey 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗮𝗿𝘁𝗶𝗰𝗹𝗲: https://lnkd.in/eQY8N2Rw #RareDisease #Biotech #Commercialization #PatientAccess #MarketAccess Fierce Biotech

What does it take for a rare disease therapy to succeed beyond launch? In a recent interview with Pharmaceutical Executive, our CEO, Bansi Nagji, shares insights on what it takes to bring rare therapies to patients and support them for the long term. In the conversation, Bansi discusses: - Why launch is only the beginning in rare disease - What sets a rare-only pharmacy model apart - How individualized patient support drives long-term success Watch the full interview to hear Bansi's perspective on the future of rare disease and the partnerships that help patients thrive: https://lnkd.in/eVbcv_Fk #PANTHERxRare #RareDisease #RareDiseasePharmacy #OrphanDrugs #PatientAccess #DrugLaunch #Pharma #Biotech #Asembia